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Objectives: To investigate the effects of a Mediterranean type diet on patients with osteoarthritis 
(OA). Participants: Ninety-nine volunteers with OA (aged 31 - 90 years) completed the study (83% 
female). Setting: Southeast of England, UK. Design: Participants were randomly allocated to the 
dietary intervention (DIET, n = 50) or control (CON, n = 49). The DIET group were asked to follow a 
Mediterranean type diet for 16 weeks whereas the CON group were asked to follow their normal diet. 
Measurements: All participants completed an Arthritis Impact Measurement Scale (AIMS2) pre-, 
mid- and post- study period. A subset of participants attended a clinic at the start and end of the study 
for assessment of joint range of motion, ROM (DIET = 33, CON = 28), and to provide blood samples 
(DIET = 29, CON = 25) for biomarker analysis (including serum cartilage oligomeric matrix protein 
(sCOMP) (a marker of cartilage degradation) and a panel of other relevant biomarkers including pro- 
and anti-inflammatory cytokines). Results: There were no differences between groups in the response 
of any AIMS2 components and most biomarkers (p > 0.05), except the pro-inflammatory cytokine IL-
Įwhich decreased in the DIET group (~47%, p = 0.010). sCOMP decreased in the DIET group by 1 
U/L (~8%, p = 0.014). There was a significant improvement in knee flexion and hip rotation ROM in 
the DIET group (p < 0.05). Conclusions: The average reduction in sCOMP in the DIET group (1 U/L) 
represents a meaningful change, but the longer term effects require further study. 
 










Often the first line of treatment for someone presenting with OA is a combination of pharmacological 
interventions, including non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics [1]. This can 
provide initial short-term benefit through an improvement in pain management and a delay to surgical 
intervention [2]. However, this does not prevent OA progression and, as it progresses, reliance on 
NSAIDs to control pain present additional complications.  Indeed, the long-term use of 
pharmacological agents (particularly NSAIDs) is associated with numerous side effects [3]. 
Consequently, such treatments are at most, moderately effective at reducing discomfort in the early 
stages of the disease [1]. Therefore, there is a need for safe and effective alternative treatments that not 
only provide symptom relief but also slow the development of the disease.  
 
It is now recognised that nutrition can play a beneficial role in some chronic diseases [4]. Eating a diet 
high in Trans and saturated fats can increase OA risk factors, as well as exacerbate current 
osteoarthritic symptoms [5]. Given the potential impact of diet on OA, empirical research is required 
to validate whether the compliance with basic dietary advice alone may improve OA symptoms 
and/or relevant biomarkers. A Mediterranean type diet (e.g. abundant in vegetables, fruits, beans, 
whole grains, olive oil and fish, and less red meat than typical Western diets) [6] has been linked with 
reductions in joint inflammation in patients with rheumatoid arthritis [7], so further work is warranted 
to examine this type of diet in patients with OA. Hence, the aim of the current study was to investigate 
the effects of a short-term (16 week) dietary intervention (in accordance with a Mediterranean type 
diet) on perceptual, functional and serum biomarkers in subjects with OA.  
 








A total of 124 volunteers with a clinician diagnosis of Osteoarthritis (aged 31-90 years) were recruited 
with 99 completing (83% female) the study.  
 
Participants were excluded if they had another health condition or co-morbidity that would make them 
unable to follow the dietary intervention; if participating in any other intervention based research; or if 
they had prior knowledge or involvement with the organisation providing the dietary advice (Arthritis 
Action, UK) to reduce the potential for control group contamination/loss of blinding.  
 
Design 
Participants were randomly allocated to one of two groups: the dietary intervention (DIET) group (n = 
50) or the control (CON) group (n = 49). From the 99 participants, a subset of 61 participants (DIET = 
33, CON = 28) attended a research clinic located at one of 3 locations in the southeast of England, UK 
(Medway, London, Eastbourne) at the start and at the end of the study. This subset was tested for their 
range of motion at the knee and hip joints and mobility of the index finger. Of these 61, blood samples 
were obtained from 54 participants (DIET = 29, CON = 25) for the assessment of biomarkers 
(samples could not be obtained from 7), and (due to equipment failure) body mass was measured for 
39 of these participants (DIET = 22, CON = 17).  
 
DIET group 
Participants mean age was 66 ± 11 y (<40 y n=2; 41-60 y n=13; 61-80 y n=29; >80 n=5) which 
comprised of n=38 females and n=11 males. Nutritional information and dietary advice were provided 
consistent with a Mediterranean diet. Support was also offered from a registered Dietician (employed 
by Arthritis Action), via telephone, which included answering questions and providing guidance on 
the diet. This intervention/advice is consistent with being member of Arthritis Action and considered 
advisable when implementing the Mediterranean diet to people from non-Mediterranean countries [8].  
  
CON group 
Participants mean age was 60 ± 12 y (<40 y n=2; 41-60 y n=22; 61-80 y n=22; >80 n=4) which 
comprised of n=44 females and n=6 males. Participants in this group followed no intervention and 
were not aware of Arthritis Action.  
 
All participants were asked to complete a 7-day food diary (as a food frequency questionnaire) and an 
Arthritis Impact Measurement Scale (AIMS2) questionnaire at the start (pre-intervention), mid-point 
(2 months) and end (4 months) of the study. All questionnaires were mailed to participants with 
Freepost return. Interpretation of the food diaries and AIMS2 questionnaires was completed by an 
Arthritis Action staff member who was blinded to the group allocation. A compliance score (from 0-
100) was calculated for each food diary.  
 
Analytical methods 
Venous blood samples were obtained by venepuncture (with minimal stasis) into untreated Vacutainer 
tubes (Becton Dickinson, Oxford, UK). After clotting, samples were centrifuged (1500 × g, 4°C) to 
obtain serum. All samples were processed within 8 hours. Serum samples were aliquotted and stored 
at - 80°C for later analysis of selected biomarkers. All samples were thawed only once prior to 
analysis. The primary biomarker was serum cartilage oligomeric matrix protein (sCOMP), because of 
previously reported relationships with OA and early-stage OA [9]. sCOMP was determined on one 
serum aliquot using an enzyme-linked immunosorbent assay (ELISA kit, AN-14-1006-71, AnaMar 
AB, Goteborg, Sweden). Secondary biomarkers included inflammatory cytokines, chemokines and 
growth factors because of established relationships with OA [10,11]. These were performed using 
multiplex panels, on a second serum aliquot, which also included some other markers (high-sensitivity 
panel with IL-ȕ,/-Į,/-2, IL-4, IL-6, IL-8, IL-10, IFN-ࢢ, TNF-Į, VEGF and EGF; and panel 
with soluble receptors IL-6sR, IL-2sR, TNF-sR1 and TNF-sR2, plus MCP-1, and MMP-9) using an 
Evidence Investigator System and biochip (EV3661 and EV3623, Randox, County Antrim, UK).  
 Ethical Approval 
This study was conducted according to the Declaration of Helsinki (2008, including 2013 
amendments) and all procedures were approved by SSES Research Ethics Advisory Group, 
University of Kent (Reference Number: Prop 56_2012_2013). Written informed consent was obtained 
from all participants. 
 
Data Analysis  
All data are presented as Means ± SD. Data were checked for standard assumptions for each statistical 
test prior to analysis. Where these were violated, data was either log or square root transformed prior 
to analysis. Differences between groups for changes over time (e.g. pre-, mid-, post-intervention) 
were assessed using mixed ANOVA (time×group). If data could not be normalised, non-parametric 
tests were used. All analysis was completed using SPSS (IBM SPSS Statistics for Windows, Version 




There was a significant difference between groups in the proportion of subjects changing dietary 
behaviour from low to high compliance (F2 p < 0.001): 30 out of the 50 participants in the DIET 
group, and only 8 of the 49 participants in the CON group, improved their compliance score from 
below to above 65 (defined as the threshold for high compliance in this study). This improvement in 
compliance in the diet group, with no change in control group was also evident for each of the subset 
analyses described below (body mass; F2 p = 0.012; biomarkers; F2 p = 0.014; range of motion; F2 p = 
0.008).  There was a significant group × time interaction (p = 0.008) for body mass with post hoc 
analysis revealing a significant reduction in the DIET group (70.4 ± 13.1 to 68.9 ± 12.6 kg, p = 
0.012), but no change in the CON group (71.6 ± 17.4 to 72.4 ± 16.6 kg, p = 0.210). 
 
Biomarkers 
There were no differences between groups in the response of any of the biomarkers measured, except 
the pro-inflammatory cytokine IL-1Į (interaction p = 0.019), which decreased pre-to post-intervention 
in the DIET group compared to no change in CON (Table 1). For sCOMP a strong trend was evident 
(interaction p = 0.057) and if explored further, at the group level, a significant pre-to post-intervention 




No significant interactions were found in any of the AIMS2 components across the study period 




Range of motion 










The main findings of the present study were that the dietary intervention was successful at changing 
eating behaviours in the DIET group, and this was associated with weight loss. The inflammatory 
cytokine IL-1Į(which has been implicated in the pathogenesis of OA, 10) was significantly reduced in 
the DIET group (but not CON). However, IL-ĮFRQFHQWUDWLRQwas higher pre-intervention in the 
DIET group (compared to CON). A similar, albeit non-significant (interaction P = 0.057) pattern was 
evident for sCOMP. When investigating groups separately, a decrease in sCOMP was evident only in 
the DIET group. This biomarker is widely regarded as a marker of cartilage degradation but has also 
recently been suggested to indicate severity of synovitis [9]. However, as with IL-Į we also 
observed a higher concentration of sCOMP at the pre-intervention time in the DIET group, compared 
to CON. Nevertheless, a decrease for both of these markers in the DIET group can be interpreted as 
beneficial, although further study is required to establish whether these decreases would continue 
further with a more prolonged intervention and thus provide long-term benefit. It is worthy of note 
that sCOMP has been identified as useful early-stage OA marker [9], so the reductions seen in the 
DIET group in a relatively short intervention period may be of more long-term, clinical, benefit. 
Changes in this marker may precede subsequent changes in physiological, functional and/or 
perceptual markers, which explain the lack of improvement in the self-reported AIMS2 questionnaire 
scores in the present study. Indeed, relatively small changes in biomarkers have been shown to 
precede any radiographic evidence of joint destruction [13]. As such, benefits to perceptual markers 
(e.g. AIMS2) may manifest after a more prolonged period. Significant improvements were seen in the 
DIET group for ROM at the hip (rotation) and knee (flexion), which may represent a functional 
benefit of the dietary intervention which has practical relevance. Taken together, these results suggest 
potential further benefit if the dietary improvements were continued in the longer-term, although this 
requires further study. Indeed, a longitudinal study (6 year follow-up) by Kumm et al. [14] 
demonstrated that sCOMP concentrations were predictive of subsequent progressive knee 
osteophytosis over the first 3 years of the study period. In this study Kumm et al.[14] demonstrated 
that an increase of 1 U/L in sCOMP concentration was associated with a 33% higher risk of knee 
osteophyte progression. Hence, the average reduction in the DIET group (1 U/L) represents a 
meaningful difference in this marker, which could be of long term clinical benefit.    
 
Body mass reductions have been shown to improve pain and function in those suffering from OA 
[15,16] and have also been shown to parallel reductions in cartilage degradation biomarkers such as 
sCOMP [16]. However, Riddle and Stratford [15] suggested that a body mass reduction in excess of 
10% is required. It is noteworthy, therefore, that the reduction in sCOMP observed in the DIET group 
(~8%) was comparable to the 10% reduction reported by Bartels et al [16] despite the relatively small 
parallel reduction in body mass (~2.2%) observed in the current study. Whilst reductions in body 
mass alone are likely significant contributors, the present findings suggest that other factors in the 
DIET group also contribute to the reduction in sCOMP. Nevertheless, body mass reduction is clearly 
important and this study has demonstrated that adherence to a Mediterranean type diet may have 
practical and clinical benefit for individuals with OA. Hence, a longer intervention period, and the 
addition of interventions that promote greater weight loss (e.g. physical activity) may be further 
beneficial, and so further study is warranted to determine the effectiveness of such interventions.   
In conclusion, the dietary intervention was successful at changing eating behaviours and this was 
associated with weight loss. In addition, the average reduction in sCOMP in the DIET group (1 U/L) 
represents a meaningful change in relation to OA [9,14], but the longer term effects of this intervention 
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